The FDA approved the first GLP-1 agonist in 2005
We understand that starting a program involving injectable medication can feel overwhelming, especially when it comes to the technicalities of handling sharps. Our platform is a user-friendly and supportive space where individuals receive personalized, medically supervised careall designed to make sustainable weight loss attainable and tailored to the individual
The assessment takes approximately two minutes to complete
J Ethnopharmacol 106, 353359, 10.1016/j.jep.2006.01.010 (2006)
Medical Disclaimer This content is for educational purposes only and not medical advice
Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data
